Skip to main content

Table 1 Patient demographics and baseline clinical characteristics

From: Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

Characteristic

ITT

n = 784

PP

n = 359

Age (years, mean ± SD)

37.1 ± 12.5;

39.3 ± 13

   (range)

18 to 26

not reported

Sex, n (%)

  

   Male

547 (69.8%)

246 (68.5%)

   Female

237 (30.2%)

113 (31.5%)

Diagnosis

  

   Schizophrenia

580 (74.0%)

266 (74.1%)

   Schizoaffective disorder

175 (22.3%)

84 (23.4%)

   Other

29 (3.7%)

9 (2.5%)

Time since diagnosis (years, mean ± SD)

10.6 ± 9.5

12.2 ± 10.4

Unemployed, n (%)

705 (89.9%)

319 (88.9%)

CGI-S score (mean ± SD)

4.52 ± 1.04

4.48 ± 1.04

Mean GAF score (mean ± SD)

42.9 ± 14.5

42.3 ± 14.5

Community treatment order

394 (50.3%)

188 (52.3%)

Full hospitalisations in previous 12-months

604 (77.0%)

267 (74.4%)

  1. CGI-S clinical global impression--severity; GAF global assessment of functioning